Smallpox vaccine
AssigneeAcambis Inc.
InventorsRichard A. Weltzin, Thomas P. Monath
Life of this patent
Estimating the term…
Abstract
The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.
Claims18
A clonal strain of attenuated vaccinia virus isolated from cell cultures in which ACAM1000 (ATCC Deposit No. PTA-3321) or a progeny strain thereof has been propagated.
A pharmaceutical composition comprising a clonal strain of vaccinia virus isolated from cell cultures in which ACAM1000 (ATCC Deposit No. PTA-3321) or a progeny strain thereof has been propagated, wherein said clonal strain is acceptably attenuated in humans when administered in an amount effective to induce a protective or therapeutic immune response against variola virus in humans and is in a form that this acceptable for administration to humans, and a pharmaceutically acceptable carrier or diluent.
A method of obtaining a clonal strain of attenuated vaccinia virus for use as a vaccine, said method comprising (i) propagating the vaccinia virus strain ACAM1000 (ATCC Deposit No. PTA-3321) or a progeny strain thereof in a cell culture system, (ii) isolating from said cell culture system a clonal strain of vaccinia virus that has substantially the same virulence, immunogenicity, growth characteristics in culture, or restriction endonuclease digestion pattern as the NYCBH strain or vaccinia virus strain ACAM1000 (ATCC Deposit No. PTA-3321), and (iii) formulating said clonal strain for administration as a vaccine.
A vaccine composition comprising a clonal strain of attenuated vaccinia virus that is obtained from cell cultures in which ACAM1000 (ATCC Deposit No. PTA-3321) has been propagated.
Dependencies are inferred from the claim text.